コーパス検索結果 (1語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 rgery patients-in particular, depression and binge eating disorder.
2 stigation towards pharmacologically treating binge eating disorder.
3 trial to test the efficacy of sibutramine in binge eating disorder.
4 e in risk is specific for the development of binge eating disorder.
5 al abuse and discrimination) in the risk for binge eating disorder.
6 ctive and well tolerated in the treatment of binge eating disorder.
7 e efficacy of sertraline in the treatment of binge eating disorder.
8 jor eating disorders and a related syndrome, Binge Eating Disorder.
9 se female patients meeting full criteria for binge eating disorder.
10 ppressant d-fenfluramine in the treatment of binge eating disorder.
11 requency of binge eating by obese women with binge eating disorder.
12 and topiramate reduced weight in adults with binge-eating disorder.
13 he characteristic symptomatology observed in binge-eating disorder.
14 as a potential pharmacological treatment for binge-eating disorder.
15 o time did any participant meet criteria for binge-eating disorder.
16 f efficacy in adults with moderate to severe binge-eating disorder.
17 ns of anorexia nervosa, bulimia nervosa, and binge-eating disorder.
18 ns of anorexia nervosa, bulimia nervosa, and binge-eating disorder.
19 t outcome measures in the acute treatment of binge-eating disorder.
20 efficacy of fluvoxamine in the treatment of binge-eating disorder.
21 derstanding of the etiology and treatment of binge eating disorders.
23 ies reporting pharmacological treatments for binge eating disorder, advances in treatment for adults
25 N=4, 0.4%) met criteria for bulimia nervosa; binge eating disorder also was more common among white w
26 f 300 overweight or obese probands (150 with binge eating disorder and 150 with no lifetime eating di
28 d bulimia nervosa and more likely to exhibit binge eating disorder and eating disorder not otherwise
29 ating and obesity, emphasizing binge eating, binge eating disorder and food addiction as useful conce
30 5 and 5 y of follow-up, 134 individuals with binge-eating disorder and 134 individuals with no histor
31 o assess longitudinally the relation between binge-eating disorder and components of the metabolic sy
32 ries are: anorexia nervosa, bulimia nervosa, binge eating disorder, and eating disorder not otherwise
40 dexamfetamine dimesylate (LDX) vs placebo in binge eating disorder (BED) was evaluated in two multice
41 teen obese individuals seeking treatment for binge eating disorder (BED) were compared with 19 non-BE
42 subjects with (n = 30) and without (n = 30) binge eating disorder (BED) were compared with matched h
43 ents the criterion standard for treatment of binge eating disorder (BED), most individuals do not hav
50 l or food, in alcohol use disorders (AUD) or binge-eating disorder (BED), suggest a disturbance in ex
54 a before and during pregnancy and those with binge-eating disorder before pregnancy exhibit dietary p
55 sorder and 2.9% had partial or full-criteria binge eating disorder but no association with the outcom
56 or attention deficit hyperactivity disorder, binge eating disorder, cocaine addiction, obesity, and t
57 ade for atypical eating disorders except for binge-eating disorder (cognitive behavioural therapy was
58 trol disorders, including gambling disorder, binge eating disorder, compulsive sexual behaviour, and
60 up intakes of women with bulimia nervosa and binge-eating disorder during pregnancy and compared thes
62 disorder criteria and had moderate to severe binge eating disorder (>/=3 binge-eating days per week f
63 sibutramine is effective in the treatment of binge eating disorder, impacting both binge eating and w
65 ce of anorexia nervosa, bulimia nervosa, and binge eating disorder in a geographically and economical
66 ciated with an increased risk for developing binge eating disorder in black women and in white women
67 Our findings support a distinct subtype of binge eating disorder in obesity with similarities in ri
68 comparison of individuals with and without a binge-eating disorder in analyses adjusted for age, sex,
69 ncts to psychotherapy for bulimia nervosa or binge-eating disorder; in the case of anorexia nervosa,
77 led group cognitive-behavioral treatment for binge eating disorder led to higher binge eating abstine
80 s among relatives with lifetime diagnoses of binge eating disorder (N=131), bulimia nervosa (N=17), a
81 gnosis of anorexia nervosa, bulimia nervosa, binge eating disorder, or eating disorder not otherwise
85 n the anticipation of rewards, subjects with binge eating disorder show greater risk-taking, similar
86 ere significantly higher in white women with binge eating disorder than in matched psychiatric compar
87 ere significantly higher in black women with binge eating disorder than in psychiatric comparison sub
88 pled with a lack of control over eating, and binge eating disorder, the Diagnostic and Statistical Ma
89 was to compare three types of treatment for binge eating disorder to determine the relative efficacy
93 icipants (N=304) who met DSM-IV criteria for binge eating disorder were randomly assigned to 24 weeks
96 es of anorexia nervosa, bulimia nervosa, and binge-eating disorder were 0.3%, 0.9%, and 1.6%, respect
97 -five outpatients with a DSM-IV diagnosis of binge-eating disorder were randomly assigned to receive
98 l, 61 outpatients (53 women, eight men) with binge eating disorder who were obese (body mass index >/
99 tablished treatments for bulimia nervosa and binge eating disorder, with stepped-care approaches show
WebLSDに未収録の専門用語(用法)は "新規対訳" から投稿できます。